Summary
Edwards Lifesciences Corporation (EW) reported strong performance in its 2016 10-K filing, highlighting significant revenue growth driven primarily by its Transcatheter Heart Valve Therapy (THVT) segment. The company continues to solidify its global leadership in structural heart disease and critical care monitoring. THVT sales saw a substantial increase, propelled by the successful launches and expanded indications of its SAPIEN family of transcatheter heart valves in key markets like the U.S. and Japan. The company's Surgical Heart Valve Therapy (SHVT) segment experienced a slight decline, attributed partly to supply constraints and product mix shifts towards THVT. However, advancements like the EDWARDS INTUITY Elite Valve System and the INSPIRIS RESILIA aortic valve show continued innovation in this area. The Critical Care segment also demonstrated growth. Overall, Edwards Lifesciences maintained a strong financial position, investing heavily in research and development to fuel future growth and expand its portfolio, particularly in areas like mitral and tricuspid valve repair. Key financial highlights include robust top-line growth and a commitment to R&D investment, representing 15.0% of net sales in 2016. The company also addressed potential risks such as competition, regulatory hurdles, and supply chain management, while actively managing its global operations and intellectual property. The acquisition of Valtech Cardio Ltd. further signals the company's strategic intent to bolster its transcatheter repair technologies.
Financial Highlights
56 data points| Revenue | $2.96B |
| Cost of Revenue | $797.40M |
| Gross Profit | $2.17B |
| R&D Expenses | $442.20M |
| SG&A Expenses | $904.70M |
| Operating Income | $751.20M |
| Interest Expense | $19.20M |
| Net Income | $569.50M |
| EPS (Basic) | $0.89 |
| EPS (Diluted) | $0.87 |
| Shares Outstanding (Basic) | 639.00M |
| Shares Outstanding (Diluted) | 653.40M |
Key Highlights
- 1Transcatheter Heart Valve Therapy (THVT) sales surged by 38.0% in 2016, becoming the largest segment and driving overall company growth.
- 2The company received multiple FDA approvals and CE Marks in 2016, expanding indications for its SAPIEN 3 and SAPIEN XT transcatheter heart valves, including for lower-risk patients and pulmonic valve replacement.
- 3Surgical Heart Valve Therapy (SHVT) sales saw a slight decrease of 1.3% in 2016, impacted by product mix shifts and supply constraints for mitral valves.
- 4Research and Development (R&D) investment increased to $443.3 million (15.0% of net sales) in 2016, reflecting a strong commitment to innovation, particularly in mitral and tricuspid valve technologies.
- 5Net sales grew by 18.8% year-over-year to $2,963.7 million in 2016.
- 6Edwards Lifesciences announced its agreement to acquire Valtech Cardio Ltd., a move expected to strengthen its position in transcatheter mitral and tricuspid valve repair.
- 7The company repurchased approximately $646.5 million of its common stock in 2016, demonstrating a commitment to returning value to shareholders.